{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:42:33Z","timestamp":1791859353733,"version":"4.3.4"},"reference-count":210,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FEDER\u2014Fundo Europeu de Desenvolvimento Regional","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"FEDER\u2014Fundo Europeu de Desenvolvimento Regional","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Portuguese funds","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"Portuguese funds","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"FCT and FEDER (European Union)","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"FCT and FEDER (European Union)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Head and neck cancers (HNCs) are known to present multiple factors likely to influence their development. This review aims to provide a comprehensive overview of the current scientific literature on the interplay between systemic inflammatory disorders, immunosuppressive treatments and their synergistic effect on HNC risk. Both cell-mediated and humoral-mediated systemic inflammatory disorders involve dysregulated immune responses and chronic inflammation and these inflammatory conditions have been associated with an increased risk of HNC development, primarily in the head and neck region. Likewise, the interaction between systemic inflammatory disorders and immunosuppressive treatments appears to amplify the risk of HNC development, as chronic inflammation fosters a tumor-promoting microenvironment, while immunosuppressive therapies further compromise immune surveillance and anti-tumor immune responses. Understanding the molecular and cellular mechanisms underlying this interaction is crucial for developing targeted prevention strategies and therapeutic interventions. Additionally, the emerging field of immunotherapy provides potential avenues for managing HNCs associated with systemic inflammatory disorders, but further research is needed to determine its efficacy and safety in this specific context. Future studies are warranted to elucidate the underlying mechanisms and optimize preventive strategies and therapeutic interventions.<\/jats:p>","DOI":"10.3390\/cells12172192","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:45:31Z","timestamp":1693557931000},"page":"2192","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers\u2014A Narrative Review of Potential Physiopathological and Biological Mechanisms"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-1459","authenticated-orcid":false,"given":"Mariana","family":"Pereira","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-8598","authenticated-orcid":false,"given":"Rui Amaral","family":"Mendes","sequence":"additional","affiliation":[{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Department of Oral and Maxillofacial Medicine and Diagnostic Sciences, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106-7401, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mahmutovi\u0107, L., Bilajac, E., and Hromi\u0107-Jahjefendi\u0107, A. (2021). Meet the Insidious Players: Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials. Microorganisms, 9.","DOI":"10.3390\/microorganisms9051001"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2006.02.016","article-title":"Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer","volume":"124","author":"Karin","year":"2006","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ejca.2006.01.004","article-title":"Inflammation, proteases and cancer","volume":"42","author":"Coussens","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_6","unstructured":"Advisory, P.-I. (2023, March 23). The Link between Periodontal Disease and Cancer: A Review. Available online: https:\/\/www.perioimplantadvisory.com\/clinical-tips\/surgical-techniques\/article\/16411685\/the-link-between-periodontal-disease-and-cancer-a-review."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zeng, X.T., Deng, A.P., Li, C., Xia, L.Y., Niu, Y.M., and Leng, W.D. (2013). Periodontal disease and risk of head and neck cancer: A meta-analysis of observational studies. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079017"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/archotol.133.5.450","article-title":"Chronic periodontitis and the risk of tongue cancer","volume":"133","author":"Tezal","year":"2007","journal-title":"Arch. Otolaryngol. Head. Neck Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1368-8375(98)80009-2","article-title":"Relationship between dental factors and risk of upper aerodigestive tract cancer","volume":"34","author":"Velly","year":"1998","journal-title":"Oral. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10549-010-1221-4","article-title":"Periodontal disease may associate with breast cancer","volume":"127","author":"Yakob","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-9255-9-46","article-title":"Inflammatory events during murine squamous cell carcinoma development","volume":"9","author":"Gasparoto","year":"2012","journal-title":"J. Inflamm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"149185","DOI":"10.1155\/2014\/149185","article-title":"Chronic Inflammation and Cytokines in the Tumor Microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7150\/ijbs.7.651","article-title":"Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression","volume":"7","author":"Zamarron","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"469150","DOI":"10.4061\/2011\/469150","article-title":"A Review of Carcinomas Arising in the Head and Neck Region in HIV-Positive Patients","volume":"2011","author":"Purgina","year":"2011","journal-title":"Pathol. Res. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hed.23283","article-title":"Cancer of the head and neck region in solid organ transplant recipients","volume":"36","author":"Rabinovics","year":"2014","journal-title":"Head. Neck"},{"key":"ref_17","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_18","first-page":"2357","article-title":"Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer","volume":"16","author":"Whiteside","year":"1996","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"899518","DOI":"10.3389\/fonc.2022.899518","article-title":"Systemic Immun e\u2013Inflammation Index as a Predictor for Head and Neck Cancer Prognosis: A Meta-Analysis","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Patini, R., Cordaro, M., Marchesini, D., Scilla, F., Gioco, G., Rupe, C., D\u2019Agostino, M.A., and Lajolo, C. (2023). Is Systemic Immunosuppression a Risk Factor for Oral Cancer? A Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15123077"},{"key":"ref_21","unstructured":"Zajac, A.J., and Harrington, L.E. (2014). Reference Module in Biomedical Sciences, Elsevier."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"825266","DOI":"10.3389\/fphar.2022.825266","article-title":"Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer","volume":"13","author":"Kumari","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5581\/1516-8484.20140016","article-title":"Oral cancer after prolonged immunosuppression for multiorgan chronic graft-versus-host disease","volume":"36","author":"Funke","year":"2014","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1182\/blood-2004-09-3411","article-title":"Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: An international case-control study","volume":"105","author":"Curtis","year":"2005","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2005.02.7052","article-title":"Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation","volume":"24","author":"Leisenring","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood-2007-07-099283","article-title":"Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: A report from the FHCRC and the EBMT-Late Effect Working Party","volume":"111","author":"Friedman","year":"2008","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/annonc\/mdt558","article-title":"Continuing increased risk of oral\/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease","volume":"25","author":"Atsuta","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/jop.12436","article-title":"Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis?","volume":"45","author":"Sonis","year":"2016","journal-title":"J. Oral Pathol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Janowiak-Majeranowska, A., Osowski, J., Mikaszewski, B., and Majeranowski, A. (2022). Secondary Oral Cancer after Systemic Treatment of Hematological Malignancies and Oral GVHD: A Systematic Review. Cancers, 14.","DOI":"10.3390\/cancers14092175"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10555-017-9694-9","article-title":"Checkpoint immunotherapy in head and neck cancers","volume":"36","author":"Zolkind","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.56.7.481","article-title":"Pathogenesis of systemic lupus erythematosus","volume":"56","author":"Mok","year":"2003","journal-title":"J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Srivastava, A., and Makarenkova, H.P. (2020). Innate Immunity and Biological Therapies for the Treatment of Sj\u00f6gren\u2019s Syndrome. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239172"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/imcb.12338","article-title":"Dysregulation of humoral immunity in chronic infection","volume":"98","author":"Cooper","year":"2020","journal-title":"Immunol. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pereira, D., Martins, D., and Mendes, F. (2022). Immunotherapy in Head and Neck Cancer When, How, and Why?. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092151"},{"key":"ref_36","first-page":"637","article-title":"Increased incidence of carcinoma of the tongue in patients with systemic sclerosis","volume":"32","author":"Derk","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/03009742.2011.618145","article-title":"Cancer risk among patients with systemic sclerosis: A nationwide population study in Taiwan","volume":"41","author":"Kuo","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/ecco-jcc\/jjv122","article-title":"Oral Cancer and Oral Precancerous Lesions in Inflammatory Bowel Diseases: A Systematic Review","volume":"9","author":"Katsanos","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/odi.12420","article-title":"Mouth cancer in inflammatory bowel diseases","volume":"22","author":"Giagkou","year":"2016","journal-title":"Oral Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.crohns.2012.03.004","article-title":"Oral squamous cell carcinoma in a Crohn\u2019s disease patient taking azathioprine: Case report and review of the literature","volume":"6","author":"Magro","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/MLG.0b013e31815abf4c","article-title":"Temporal relationship between antitumor necrosis factor-alpha antibody therapy and recrudescence of head and neck squamous cell carcinoma","volume":"118","author":"Engel","year":"2008","journal-title":"Laryngoscope"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00042737-200302000-00013","article-title":"Neoplasia of the tongue in a patient with Crohn\u2019s disease treated with azathioprine: Case report","volume":"15","author":"Li","year":"2003","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/00016489.2013.800228","article-title":"Impact of head and neck malignancies on risk factors and survival in systemic lupus erythematosus","volume":"133","author":"Chang","year":"2013","journal-title":"Acta Otolaryngol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00432-015-2032-0","article-title":"Systemic lupus erythematosus and malignancies risk","volume":"142","author":"Mao","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cao, L., Tong, H., Xu, G., Liu, P., Meng, H., Wang, J., Zhao, X., Tang, Y., and Jin, J. (2015). Systemic lupus erythematous and malignancy risk: A meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122964"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1150.e1","DOI":"10.1016\/j.amjmed.2010.08.006","article-title":"Malignancy in systemic lupus erythematosus: A nationwide cohort study in Taiwan","volume":"123","author":"Chen","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13075-021-02648-y","article-title":"Increased risk of malignancy in patients with systemic lupus erythematosus: Population-based cohort study in Korea","volume":"23","author":"Han","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0961203310383068","article-title":"Squamous cell carcinoma on the palate in a patient with systemic lupus erythematosus: Case report and review of literature","volume":"20","year":"2011","journal-title":"Lupus"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"bcr2013008864","DOI":"10.1136\/bcr-2013-008864","article-title":"Systemic lupus erythematosus, pregnancy and carcinoma of the tongue","volume":"2013","author":"Unsworth","year":"2013","journal-title":"BMJ Case Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.joms.2015.05.022","article-title":"Oral Squamous Cell Carcinoma Presenting in a Patient Receiving Adalimumab for Rheumatoid Arthritis","volume":"73","author":"Beattie","year":"2015","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.oooo.2013.11.499","article-title":"Oropharyngeal carcinoma arising after methotrexate and etanercept therapy for rheumatoid arthritis","volume":"117","author":"Chang","year":"2014","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Phillips, C., Zeringue, A.L., McDonald, J.R., Eisen, S.A., and Ranganathan, P. (2015). Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143286"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1053\/joms.2001.25033","article-title":"Tongue carcinoma in a young patient with dermatomyositis: A case report and review of the literature","volume":"59","author":"Sugiyama","year":"2001","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/hed.23703","article-title":"Dermatomyositis paraneoplastic syndrome before symptomatic tonsillar squamous cell carcinoma: A case report","volume":"37","author":"Adi","year":"2015","journal-title":"Head. Neck"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00296-003-0319-y","article-title":"Dermatomyositis and malignancy of the pharynx in Caucasian patients: Report of two observations","volume":"23","author":"Botsios","year":"2003","journal-title":"Rheumatol. Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/014107688307600916","article-title":"Dermatomyositis and salivary pleomorphic adenoma","volume":"76","author":"Holden","year":"1983","journal-title":"J. R. Soc. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3349\/ymj.2010.51.4.605","article-title":"Tonsillar squamous cell carcinoma associated with dermatomyositis: The first 2 cases in Korea","volume":"51","author":"Kim","year":"2010","journal-title":"Yonsei Med. J."},{"key":"ref_58","first-page":"340","article-title":"[Dermatomyositis\/polymyositis associated with head and neck malignancy]","volume":"19","author":"Liu","year":"2005","journal-title":"Lin. Chuang Er Bi Yan Hou Ke Za Zhi"},{"key":"ref_59","first-page":"401","article-title":"Nasopharyngeal carcinoma and dermatomyositis (analysis of 12 cases)","volume":"12","author":"Song","year":"1998","journal-title":"Lin. Chuang Er Bi Yan Hou Ke Za Zhi"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archotol.1995.01890110072013","article-title":"Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases","volume":"121","author":"Peng","year":"1995","journal-title":"Arch. Otolaryngol. Head. Neck Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1067\/mjd.2003.208","article-title":"Dermatomyositis and malignancy in Tunisia: A multicenter national retrospective study of 20 cases","volume":"48","author":"Boussen","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"843","DOI":"10.47102\/annals-acadmedsg.V39N11p843","article-title":"An 11-year review of dermatomyositis in Asian patients","volume":"39","author":"Liu","year":"2010","journal-title":"Ann. Acad. Med. Singap."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0360-3016(89)90344-1","article-title":"Nasopharyngeal carcinoma with dermatomyositis","volume":"16","author":"Teo","year":"1989","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcv.2010.08.015","article-title":"Polymyositis\/dermatomyositis and nasopharyngeal carcinoma: The Epstein-Barr virus connection?","volume":"49","author":"Chen","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1346-8138.1998.tb02451.x","article-title":"Dermatomyositis and nasopharyngeal carcinoma","volume":"25","author":"Abraham","year":"1998","journal-title":"J. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1046\/j.0022-202x.2001.01520.x","article-title":"Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden","volume":"117","author":"Boffetta","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","article-title":"Malignant tumours and psoriasis: A follow-up study","volume":"140","author":"Frentz","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1523-1747.2000.00898.x","article-title":"Psoriasis, its treatment, and cancer in a cohort of Finnish patients","volume":"114","author":"Pukkala","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1902\/jop.2009.090370","article-title":"Gingival mucinous adenocarcinoma of a minor salivary gland","volume":"81","author":"Seoane","year":"2010","journal-title":"J. Periodontol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/039463201202500135","article-title":"Occurrence of salivary gland tumours in two patients treated with biological agents","volume":"25","author":"Carlesimo","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000246213","article-title":"Adenocarcinoma of the mouth in a patient with psoriasis under short-term cyclosporine therapy","volume":"193","author":"Yamamoto","year":"1996","journal-title":"Dermatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/art.1780370218","article-title":"Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud\u2019s phenomenon","volume":"37","author":"Higley","year":"1994","journal-title":"Arthritis Rheum."},{"key":"ref_73","first-page":"122","article-title":"The significance of interleukin-6 and C-reactive protein in systemic sclerosis: A systematic literature review","volume":"31","author":"Muangchant","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2249.2004.02642.x","article-title":"Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement","volume":"138","author":"Scala","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.1780350111","article-title":"Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma","volume":"35","author":"Needleman","year":"1992","journal-title":"Arthritis Rheum."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/art.1780350814","article-title":"Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis","volume":"35","author":"Takemura","year":"1992","journal-title":"Arthritis Rheum."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17 production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_78","first-page":"1524","article-title":"Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis","volume":"30","author":"Furuse","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/rheumatology\/34.11.1048","article-title":"Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis","volume":"34","author":"Denton","year":"1995","journal-title":"Br. J. Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"Affandi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2010.10.011","article-title":"The role of the CXC chemokines platelet factor-4 (CXCL4\/PF-4) and its variant (CXCL4L1\/PF-4var) in inflammation, angiogenesis and cancer","volume":"22","author":"Vandercappellen","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00269199","article-title":"Presence of interferon and anti-interferon in patients with systemic lupus erythematosus","volume":"8","author":"Jakschies","year":"1988","journal-title":"Rheumatol. Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.1780330414","article-title":"Serum activity that confers acid lability to alpha-interferon in systemic lupus erythematosus: Its association with disease activity and its independence from circulating alpha-interferon","volume":"33","author":"Yee","year":"1990","journal-title":"Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/anr.1780320206","article-title":"Tumor necrosis factor in the serum of patients with systemic lupus erythematosus","volume":"32","author":"Maury","year":"1989","journal-title":"Arthritis Rheum."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/03009748909099924","article-title":"Defective phagocytosis, decreased tumour necrosis factor-alpha production, and lymphocyte hyporesponsiveness predispose patients with systemic lupus erythematosus to infections","volume":"18","author":"Yu","year":"1989","journal-title":"Scand. J. Rheumatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1073\/pnas.87.3.1233","article-title":"Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus","volume":"87","author":"Jacob","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","first-page":"80","article-title":"T cell function in systemic lupus erythematosus: Normal production of and responsiveness to interleukin 2","volume":"64","author":"Draeger","year":"1986","journal-title":"Clin. Exp. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0090-1229(84)90118-1","article-title":"Lymphokines in autoimmunity: Relationship between interleukin-2 and interferon-gamma production in systemic lupus erythematosus","volume":"32","author":"Sibbitt","year":"1984","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/art.1780311103","article-title":"Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation","volume":"31","author":"Campen","year":"1988","journal-title":"Arthritis Rheum."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/ard.48.10.803","article-title":"Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus","volume":"48","author":"Tokano","year":"1989","journal-title":"Ann. Rheum. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1191\/096120399678847489","article-title":"The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity","volume":"8","author":"Ohtsuka","year":"1999","journal-title":"Lupus"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1084\/jem.166.3.798","article-title":"In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon","volume":"166","author":"Jacob","year":"1987","journal-title":"J. Exp. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/1043-4666(91)90481-R","article-title":"Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: Implications for genetic predisposition and immune regulation","volume":"3","author":"Jacob","year":"1991","journal-title":"Cytokine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/rheumatology\/31.5.293","article-title":"TNF alpha--a pivotal role in rheumatoid arthritis?","volume":"31","author":"Brennan","year":"1992","journal-title":"Br. J. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2005-11-4567","article-title":"TNF downmodulates the function of human CD4+CD25hi T-regulatory cells","volume":"108","author":"Valencia","year":"2006","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm0297-189","article-title":"Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis","volume":"3","author":"McInnes","year":"1997","journal-title":"Nat. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1084\/jem.170.3.865","article-title":"Cytokines in chronic inflammatory arthritis. IV. Granulocyte\/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: A possible role in rheumatoid arthritis","volume":"170","author":"Zvaifler","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","article-title":"Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1541-7786.MCR-12-0276","article-title":"Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth","volume":"10","author":"Hsu","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cyto.2007.10.004","article-title":"The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy","volume":"41","author":"Kragstrup","year":"2008","journal-title":"Cytokine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_102","unstructured":"Surgeons, T. (2023, April 05). Inflammatory Bowel Disease (IBD). Available online: https:\/\/www.thesurgeons.sg\/services\/inflammatory-bowel-disease\/."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","article-title":"Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases","volume":"140","author":"Strober","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4137\/CGast.S20612","article-title":"Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn\u2019s Colitides","volume":"8","author":"Korolkova","year":"2015","journal-title":"Clin. Med. Insights Gastroenterol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaut.2006.02.003","article-title":"Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn\u2019s disease","volume":"26","author":"Rahbar","year":"2006","journal-title":"J. Autoimmun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"690853","DOI":"10.1155\/2014\/690853","article-title":"Serum Interleukin 17 Levels in Patients with Crohn\u2019s Disease: Real Life Data","volume":"2014","author":"Sahin","year":"2014","journal-title":"Dis. Markers"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: An inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archdermatol.2009.48","article-title":"Psoriasis and the risk of diabetes and hypertension: A prospective study of US female nurses","volume":"145","author":"Qureshi","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2009.02.015","article-title":"The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis","volume":"61","author":"Makredes","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bjd.12355","article-title":"Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis","volume":"169","author":"Dowlatshahi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: An association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MD.0b013e3181ca14ff","article-title":"Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy","volume":"89","author":"Palou","year":"2010","journal-title":"Medicine"},{"key":"ref_117","first-page":"101","article-title":"Dermatomyositis and polymyositis: From immunopathology to immunotherapy (immunobiologics)","volume":"53","author":"Shinjo","year":"2013","journal-title":"Rev. Bras. Reumatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11926-011-0166-x","article-title":"Pathogenesis of dermatomyositis: Role of cytokines and interferon","volume":"13","author":"Kao","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaut.2010.07.006","article-title":"Characterization of regulatory T cells in patients with dermatomyositis","volume":"35","author":"Antiga","year":"2010","journal-title":"J. Autoimmun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00296-010-1692-y","article-title":"Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: Correlation to disease activity","volume":"32","author":"Mielnik","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_122","unstructured":"Gary S Firestein, M., and Monica Guma, M. (2023, March 29). Pathogenesis of Rheumatoid Arthritis. Available online: https:\/\/www.uptodate.com\/contents\/pathogenesis-of-rheumatoid-arthritis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/ard.36.1.13","article-title":"Cell-mediated immunity in rheumatoid arthritis","volume":"36","author":"Andrianakos","year":"1977","journal-title":"Ann. Rheum. Dis."},{"key":"ref_124","first-page":"193","article-title":"Depression of cell-mediated immunity in old age and the immunopathic diseases, lupus erythematosus, chronic hepatitis and rheumatoid arthritis","volume":"14","author":"Toh","year":"1973","journal-title":"Clin. Exp. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.01018.x","article-title":"Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA)","volume":"118","author":"Yanagihara","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"491974","DOI":"10.1100\/2012\/491974","article-title":"Natural killer cells and their role in rheumatoid arthritis: Friend or foe?","volume":"2012","author":"Shegarfi","year":"2012","journal-title":"Sci. World J."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Radstake, T.R.D.J., van Bon, L., Broen, J., Hussiani, A., Hesselstrand, R., Wuttge, D.M., Deng, Y., Simms, R., Lubberts, E., and Lafyatis, R. (2009). The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGF\u03b2 and IFN\u03b3 Distinguishes SSc Phenotypes. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005903"},{"key":"ref_128","first-page":"235","article-title":"Selective decrease in antibody-dependent cell-mediated cytotoxicity in systemic lupus erythematosus and progressive systemic sclerosis","volume":"34","author":"Cooper","year":"1978","journal-title":"Clin. Exp. Immunol."},{"key":"ref_129","first-page":"233","article-title":"The relationship of defective cell-mediated immunity to visceral disease in systemic sclerosis","volume":"28","author":"Hughes","year":"1977","journal-title":"Clin. Exp. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.hemonc.2014.11.006","article-title":"Natural killer cells: In health and disease","volume":"8","author":"Mandal","year":"2015","journal-title":"Hematol.\/Oncol. Stem Cell Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/imm.12114","article-title":"Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation","volume":"140","author":"Funderburg","year":"2013","journal-title":"Immunology"},{"key":"ref_132","first-page":"351","article-title":"Depressed spontaneous cell-mediated cytotoxicity in Crohn\u2019s disease","volume":"51","author":"Beeken","year":"1983","journal-title":"Clin. Exp. Immunol."},{"key":"ref_133","first-page":"187","article-title":"Natural killer cell activity in patients with inflammatory bowel disease","volume":"20","author":"Egawa","year":"1986","journal-title":"J. Clin. Lab. Immunol."},{"key":"ref_134","first-page":"449","article-title":"Cell-mediated immune response in psoriasis and psoriatic arthritis","volume":"80","author":"Ventura","year":"1989","journal-title":"Recent. Prog. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2133.2003.05319.x","article-title":"Circulating natural killer cells in psoriasis","volume":"149","author":"Cameron","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000328011","article-title":"Natural Killer Cells in Psoriasis","volume":"3","author":"Tobin","year":"2011","journal-title":"J. Innate Immun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/BF00407735","article-title":"Defective natural-killer- and killer-cell activity associated with increased polymorphonuclear leukocyte adherence in psoriasis","volume":"278","author":"Majewski","year":"1986","journal-title":"Arch. Dermatol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"248317","DOI":"10.1155\/2011\/248317","article-title":"NK Cells and Psoriasis","volume":"2011","author":"Dunphy","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar2885","article-title":"Type 1 interferons and myositis","volume":"12","author":"Greenberg","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/ard.2003.017715","article-title":"Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis","volume":"64","author":"Aleksza","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/CDLI.7.4.693-697.2000","article-title":"Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis","volume":"7","author":"Bianchi","year":"2000","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/rheumatology\/kel119","article-title":"Decreased CD161+CD8+ T cells in the peripheral blood of patients suffering from rheumatic diseases","volume":"45","author":"Mitsuo","year":"2006","journal-title":"Rheumatology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00005792-200303000-00002","article-title":"Peripheral blood lymphocyte subset counts in patients with dermatomyositis: Clinical correlations and changes following therapy","volume":"82","author":"Viguier","year":"2003","journal-title":"Medicine"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/cdli.2.2.205-208.1995","article-title":"Flow cytometric analyses of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis","volume":"2","author":"Corrochano","year":"1995","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1346-8138.1993.tb03825.x","article-title":"Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis","volume":"20","author":"Ishida","year":"1993","journal-title":"J. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10067-012-2075-4","article-title":"Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis","volume":"31","author":"Wang","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies","volume":"10","author":"Brattsand","year":"1996","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.7326\/0003-4819-119-12-199312150-00007","article-title":"Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.immunol.18.1.309","article-title":"Glucocorticoids in T cell development and function*","volume":"18","author":"Ashwell","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2249.1996.tb08306.x","article-title":"Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes","volume":"103","author":"Lanza","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0167-0115(97)01063-X","article-title":"Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures","volume":"73","author":"Franchimont","year":"1998","journal-title":"Regul. Pept."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood.V91.11.4255","article-title":"Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro","volume":"91","author":"Visser","year":"1998","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.4049\/jimmunol.164.4.1768","article-title":"Inhibition of Th1 immune response by glucocorticoids: Dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes","volume":"164","author":"Franchimont","year":"2000","journal-title":"J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.immuni.2006.06.002","article-title":"Th17: An effector CD4 T cell lineage with regulatory T cell ties","volume":"24","author":"Weaver","year":"2006","journal-title":"Immunity"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","article-title":"Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids","volume":"211","author":"Ramesh","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08923977909040545","article-title":"The effects of azathioprine and 6 MP on immunity","volume":"1","author":"Winkelstein","year":"1979","journal-title":"J. Immunopharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.imlet.2011.06.010","article-title":"The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals","volume":"140","author":"Leitner","year":"2011","journal-title":"Immunol. Lett."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.crohns.2012.06.020","article-title":"\u201cIn vitro\u201d azathioprine-induced changes in peripheral T cell apoptosis and IFN-\u03b3 production associate with drug response in patients with Crohn\u2019s Disease","volume":"7","author":"Cossu","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1749-6632.1998.tb11129.x","article-title":"Azathioprine, Mycophenolate Mofetil, and Methotrexate Specifically Modulate Cytokine Production by T Cells","volume":"859","author":"Hildner","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.2010.04309.x","article-title":"Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia","volume":"164","author":"Vanoye","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MEG.0b013e32834233a2","article-title":"Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: A prospective observational study","volume":"23","author":"Prasad","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ibd.20004","article-title":"Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease","volume":"13","author":"Stocco","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: Golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2015.06.009","article-title":"High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP1\/CD107a-expressing CD4-positive T cells into tumor sites","volume":"366","author":"Naito","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","article-title":"Low dose cyclophosphamide: Mechanisms of T cell modulation","volume":"42","author":"Madondo","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.1982.tb00429.x","article-title":"Effect of cyclophosphamide on immunological control mechanisms","volume":"65","author":"Turk","year":"1982","journal-title":"Immunol. Rev."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1172\/JCI108080","article-title":"Cyclophosphamide suppression of established cell-mediated immunity. Quantitative vs. qualitative changes in lymphocyte populations","volume":"56","author":"Balow","year":"1975","journal-title":"J. Clin. Investig."},{"key":"ref_170","first-page":"141","article-title":"Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide","volume":"16","author":"Motoyoshi","year":"2006","journal-title":"Oncol. Rep."},{"key":"ref_171","unstructured":"Hardinger, K., and Magee, C.C. (2023, March 30). Pharmacology of Cyclosporine and Tacrolimus. Available online: https:\/\/www.uptodate.com\/contents\/pharmacology-of-cyclosporine-and-tacrolimus."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol. Today"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/art.1780400622","article-title":"In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): Experience in patients with Beh\u00e7et\u2019s disease","volume":"40","author":"Suzuki","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann. N. Y Acad. Sci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/383837a0","article-title":"Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression","volume":"383","author":"Timmerman","year":"1996","journal-title":"Nature"},{"key":"ref_176","first-page":"324","article-title":"Divergent effect of cyclosporine on Th1\/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis","volume":"27","author":"Kim","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/B:JOCI.0000029107.47085.1b","article-title":"Systemic Treatment with Either Cyclosporin A or Methotrexate Does Not Influence the T Helper 1\/T Helper 2 Balance in Psoriatic Patients","volume":"24","author":"Rentenaar","year":"2004","journal-title":"J. Clin. Immunol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00007890-199802150-00003","article-title":"In vivo expression of transforming growth factor-beta1 in humans: Stimulation by cyclosporine","volume":"65","author":"Shin","year":"1998","journal-title":"Transplantation"},{"key":"ref_179","first-page":"106","article-title":"Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA","volume":"22","author":"Zeevi","year":"1990","journal-title":"Transplant. Proc."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/eji.1830110812","article-title":"Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2","volume":"11","author":"Bunjes","year":"1981","journal-title":"Eur. J. Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.febslet.2011.04.025","article-title":"Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity","volume":"585","author":"Chen","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.imbio.2011.07.006","article-title":"Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-\u03b3-producing NK cell and regulatory T cell subsets","volume":"216","author":"Aravena","year":"2011","journal-title":"Immunobiology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.intimp.2015.11.005","article-title":"Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-\u03b1 treatment in psoriasis","volume":"29","author":"Luan","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.4049\/jimmunol.159.12.6253","article-title":"Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram","volume":"159","author":"Ross","year":"1997","journal-title":"J. Immunol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/03009742.2012.754937","article-title":"Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis","volume":"42","author":"Eriksson","year":"2013","journal-title":"Scand. J. Rheumatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/CVI.00061-11","article-title":"Distinct effects of anti-tumor necrosis factor combined therapy on TH1\/TH2 balance in rheumatoid arthritis patients","volume":"18","author":"Herman","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/art.34565","article-title":"Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy","volume":"64","author":"McGovern","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clim.2011.01.015","article-title":"Dual role of anti-TNF therapy: Enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues","volume":"139","author":"Raeli","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10875-015-0182-0","article-title":"Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: A Possible Explanation for a Lack of Clinical Response","volume":"35","author":"Talotta","year":"2015","journal-title":"J. Clin. Immunol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10067-013-2352-x","article-title":"The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: A follow-up study","volume":"33","author":"Szalay","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3109\/00365521.2015.1031167","article-title":"Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy","volume":"50","author":"Magnusson","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/ijd.12706","article-title":"Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-\u03b1 inhibitors: Results of a retrospective analysis","volume":"54","author":"Campanati","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00002281-199905000-00012","article-title":"Molecular and cellular effects of methotrexate","volume":"11","author":"Seitz","year":"1999","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1572-0241.2003.07305.x","article-title":"Low dose methotrexate in inflammatory bowel disease: Current status and future directions","volume":"98","author":"Stein","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: An old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/1744666X.2015.1026894","article-title":"Systemic methotrexate for the treatment of psoriasis","volume":"11","author":"Puig","year":"2015","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.biopha.2010.01.007","article-title":"Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+ CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines","volume":"64","author":"Xinqiang","year":"2010","journal-title":"Biomed. Pharmacother."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1211\/0022357022269","article-title":"Effect of methotrexate on Th1 and Th2 immune responses in mice","volume":"55","author":"Yamaki","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_207","first-page":"317","article-title":"Methotrexate selectively modulates TH1\/TH2 balance in active rheumatoid arthritis patients","volume":"26","author":"Herman","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00109-003-0460-9","article-title":"A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses","volume":"81","author":"Ghoreschi","year":"2003","journal-title":"J. Mol. Med."},{"key":"ref_209","first-page":"1075","article-title":"Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosus","volume":"24","author":"Dayan","year":"1997","journal-title":"J. Rheumatol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/17\/2192\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:44:52Z","timestamp":1760129092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/17\/2192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":210,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cells12172192"],"URL":"https:\/\/doi.org\/10.3390\/cells12172192","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}